Patents Examined by Sagar Patel
  • Patent number: 11124479
    Abstract: The invention relates to compounds and pharmaceutical compositions capable of treating amyloid diseases and other diseases characterized by oligomerization and/or fibrillation of amyloidogenic peptides such as islet amyloid polypeptide (IAPP).
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 21, 2021
    Inventors: Andrew D. Hamilton, Sunil Kumar
  • Patent number: 11117883
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
  • Patent number: 11111221
    Abstract: A method for stabilization of collagen matrices and of condensation of natural and synthetic polymers that uses 2-halo-4, 6-dialkoxy-1, 3, 5-triazines in the presence of one or more amines as activating agents for reactions of crosslinking, condensation, grafting, and curing of collagen matrices, cellulose, modified celluloses, polysaccharides, acid unsaturated polymers, and chiral and non-chiral amines, etc. Forming an integral part of the present invention is also the method for production on an industrial scale of 2-halo-4, 6-dialkoxy-1, 3, 5-triazines.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 7, 2021
    Assignee: CROSSING SRL
    Inventor: Valentina Beghetto
  • Patent number: 11104767
    Abstract: Use of 2,4-dihalo-6-substituted-1,3,5-triazines as condensing, cross-linking, tanning, grafting, curing agents for the production of amides, esters, thioesters, and stabilized collagen and leather, CMC (carboxymethyl cellulose), synthetic and natural polymers. The process enables to obtain non-toxic and totally free of heavy metals products characterized by Tg values between 80° C. and 100° C.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 31, 2021
    Assignee: CROSSING SRL
    Inventors: Valentina Beghetto, Lodovico Agostinis
  • Patent number: 11104693
    Abstract: The present disclosure is directed to methods for dehydrogenatively coupled hydrosilanes and alcohols, the methods comprising contacting an organic substrate having at least one organic alcohol moiety with a mixture of at least one hydrosilane and sodium and/or potassium hydroxide, the contacting resulting in the formation of a dehydrogenatively coupled silyl ether. The disclosure further described associated compositions and methods of using the formed products.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 31, 2021
    Assignee: California Institute of Technology
    Inventors: Anton Toutov, Kerry Betz, Andrew M. Romine, Robert H. Grubbs
  • Patent number: 11091501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
  • Patent number: 11084833
    Abstract: Antibacterial agents against D,D- and L,D-transpeptidases are disclosed. Pharmaceutical compositions and methods of using the same also are disclosed.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: August 10, 2021
    Assignee: The Johns Hopkins University
    Inventors: Craig A. Townsend, Evan Lloyd
  • Patent number: 11078156
    Abstract: A process is provided for control of an ammoxidation reactor. More specifically, the process includes controlling an amount of oxygen added to the reactor, steam temperature and linear velocity to minimize reactor temperature deviations.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 3, 2021
    Assignee: INEOS EUROPE AG
    Inventors: Manoj Shrikant Shouche, Timothy Robert McDonel, Jay Robert Couch
  • Patent number: 11078163
    Abstract: The present invention concerns a process for preparing a compound having the Formula A; or a pharmaceutically acceptable salt or derivative thereof, or for preparing a substituted urea compound of Formula IIa, or a pharmaceutically acceptable salt or ester thereof, the process comprising the reaction of an imidazolyl intermediate of Formula IIa? with a carbamoyl halide of the formula: R1R2NC(?O)Hal, wherein Hal represents Cl, F, I or Br, wherein the intermediate of Formula IIa? is prepared by oxidation of the derivative of R5 and R6, R6-C(?O)CH2R5 to form a glyoxal intermediate R6-C(?O)(C?O)R5, which is subjected to treatment with ammonium hydroxide and an aldehyde R8CHO to provide the intermediate of Formula IIa? and wherein the compound substituents are as defined herein.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 3, 2021
    Assignee: BIAL-PORTELA & Cª, S.A.
    Inventors: Domenico Russo, Jorge Bruno Reis Wahnon, William Maton, Tibor Eszenyi
  • Patent number: 11078152
    Abstract: The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(?) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: August 3, 2021
    Assignee: Universite de Rouen
    Inventors: Gérard Coquerel, Julien Mahieux, François-Xavier Gendron
  • Patent number: 11072608
    Abstract: Compounds of formula I(I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 27, 2021
    Inventors: Ottmar Franz Hueter, Andrew Edmunds, Andre Jeanguenat, Pierre Joseph Marcel Jung, Anke Buchholz, Michel Muehlebach
  • Patent number: 11065260
    Abstract: A method of reducing mortality in a human patient with pulmonary inflammation due to coronavirus or other pathogen, the method including administering an oral dose of a prostacyclin analog drug to the patient within a therapeutic window. The prostacyclin analog drug includes oral iloprost or iloprost betadex clathrate.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: July 20, 2021
    Inventors: Alan C Nelson, Daniel J Sussman
  • Patent number: 11066374
    Abstract: Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: July 20, 2021
    Inventors: Teruhiko Ishikawa, Morita Iwami
  • Patent number: 11059766
    Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: July 13, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
  • Patent number: 11053255
    Abstract: Disclosed herein are methods of synthesizing mahanine and related compounds. The synthesis features an intramolecular aryl-alkyne isomerization, transition metal catalyzed cross-coupling and intramolecular carbazole forming reaction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 6, 2021
    Inventors: Milton L. Brown, Shujie Hou
  • Patent number: 11053254
    Abstract: Synthesis and characterization of novel crystalline mitomycin C forms suitable for pharmaceutical compositions in drug delivery systems to treat human or warm-blooded diseases.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 6, 2021
    Inventors: Mazen Hanna, Manomi Perera, Jiyu Yan, Andrew Hanna
  • Patent number: 11046692
    Abstract: Described herein are compounds of Formulae (I?)-(II?), compounds of Formulae (I)-(II) and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful for modulating opioid receptor activity. The provided compounds may have both agonistic and antagonistic effect on one or more opioid receptors. Methods of using the compounds for treating or managing pain are also described.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 29, 2021
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gavril Pasternak, Susruta Majumdar, Rashad Karimov, Andras Varadi
  • Patent number: 11034683
    Abstract: The present invention relates to the novel key intermediate, 4-{4-[(5S)-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, in the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method of preparing rivaroxaban using this novel intermediate. The invention provides an improved and efficient process for preparation of Rivaroxaban.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 15, 2021
    Inventors: Dhananjay G. Sathe, Arijit Das, Sanjay Raikar, Yashwant S. Surve, Bhushan S. Pandit
  • Patent number: 11034659
    Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: June 15, 2021
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Yamato Suzuki, Toshiharu Noji, Hidenobu Murafuji, Satoshi Muneoka, Hidekazu Inoue, Bitoku Takahashi, Rie Inaba
  • Patent number: 11021474
    Abstract: The present invention relates to the field of anti-viral active agents, particularly the free base hemihydrate form of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide as well as methods for the manufacture thereof. The present invention relates also to the use of the above compound in the treatment of human herpes virus infections and in the preparation of pharmaceuticals comprising said compound.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: June 1, 2021
    Assignee: AiCuris Anti-Infective Cures GmbH
    Inventors: Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Kurt Voegtli